Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace | Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
Insmed CEO Will Lewis talked to Evaluate about the biotech’s orphan drug strategy, why it is still committed to rare diseases, and how orphan drug benefits might be better targeted.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
